Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

Indian J Pharmacol. 2020 Sep-Oct;52(5):441-442. doi: 10.4103/ijp.IJP_417_20.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Lymphopenia / epidemiology
  • Lymphopenia / etiology
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / drug therapy*
  • Pandemics*
  • Risk

Substances

  • Immunosuppressive Agents